Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Top Cited Papers
- 1 November 2011
- journal article
- practice guideline
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (31) , 4189-4198
- https://doi.org/10.1200/jco.2010.34.4614
Abstract
Purpose To update the American Society of Clinical Oncology (ASCO) guideline for antiemetics in oncology. Methods A systematic review of the medical literature was completed to inform this update. ...Keywords
This publication has 31 references indexed in Scilit:
- Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III studySupportive Care in Cancer, 2010
- Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhoodPublished by Wiley ,2010
- Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trialSupportive Care in Cancer, 2010
- Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapyAnnals of Oncology, 2010
- The Missing Voice of Patients in Drug-Safety ReportingNew England Journal of Medicine, 2010
- Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomitingJournal of Experimental & Clinical Cancer Research, 2009
- Aprepitant in adolescent patients for prevention of chemotherapy‐induced nausea and vomiting: A randomized, double‐blind, placebo‐controlled study of efficacy and tolerabilityPediatric Blood & Cancer, 2008
- The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trialSupportive Care in Cancer, 2008
- 5-Hydroxytryptamine-3 Receptor Antagonist With or Without Short-Course Dexamethasone in the Prophylaxis of Radiation Induced Emesis: A Placebo-Controlled Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (SC19)Journal of Clinical Oncology, 2006
- Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemeticsCancer, 2003